|
Immunomedics is focused on developing humanized monoclonal antibodies (MAbs) to treat cancer and other serious diseases. Its lead product, epratuzumab, is in late-stage development for the treatment of lupus; biopharmaceutical firm UCB has licensed the drug for further applications in autoimmune diseases. Immunomedics is also conducting clinical trials for epratuzumab as an oncology treatment for non-Hodgkin's lymphoma and leukemia. The company has other drugs in clinical trials to treat various cancers, including veltuzumab (lymphoma) and milatuzumab (multiple myeloma). It also makes diagnostic imaging products; subsidiary IBC Pharmaceuticals develops radiotherapeutics for applications in oncology treatments.
|
| | | Contact Information | |
Address: |
300 American Rd.
Morris Plains, NJ 07950
| | Phone: | 973-605-8200 | | Fax: | 973-605-8282 |
|
| Financial
Highlights | | Fiscal Year End: | June | | Revenue (2009): | 30.00 M | | Revenue Growth (1 yr): | 722.30% | | Employees (2009): | 120 | | Employee Growth (1 yr): | 2.60% |
|
|
Key People
| | • |
Chairman, Chief Strategic Officer, Chief Sceintific Officer,:
David M. Goldenberg
| | • |
President, CEO, and Director:
Cynthia L. Sullivan
| | • |
SVP Finance and Business Development, and CFO:
Gerard G. (Gerry) Gorman
|
|
|
